Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cometriq

- PMLiVE

Cancer Drugs Fund “may have harmed patients”

Researchers claim most CDF drugs failed to show benefits to patients

- PMLiVE

NICE turns down first-line Keytruda for lung cancer

High cost of drug puts it above cost-effectiveness threshold

Roche Basel Switzerland

Tecentriq growth offsets Avastin’s US decline at Roche

Shifts focus to newer therapies in anticipation of brewing biosimilar competition

- PMLiVE

NICE U-turn on Novartis’ Afinitor for kidney cancer

Set to back treatment's routine NHS use following offer of discount and new data

- PMLiVE

Boehringer says Avastin biosimilar on track as Phase III gets underway

Clinical data suggests candidate has same biologic profile as Roche’s cancer drug

Bristol-Myers Squibb (BMS) building

NICE U-turn on Opdivo for kidney cancer

BMS sways the watchdog with new data and a patient access scheme

Roche Basel Switzerland

Roche in “unprecedented” launch period for new medicines

Cotellic, Alecensa, Venclexta and Tecentriq position firm to meet 2016 sales targets

- PMLiVE

Shire wins EU licence for pancreatic cancer drug Onivyde

Combination treatment is the first approved for this patient population

Bristol-Myers Squibb (BMS) building

NICE turns down Opdivo but offers CDF hope

Wants more cost-effectiveness data to be gathered

- PMLiVE

Tesaro’s niraparib threatens Lynparza after acing ovarian cancer trial

Maintenance therapy significantly improved progression-free survival regardless of BRCA status

- PMLiVE

Reformed Cancer Drugs Fund backs its first drug – AZ’s Tagrisso

Lung cancer treatment will be available to NHS patients while NICE awaits data

- PMLiVE

NICE backs Bayer’s Eylea as first-line BRVO treatment

Recommends visual impairment therapy over current laser treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links